PEGylated oxyntomodulin long acting (MOD-6031) / OPKO Health - LARVOL DELTA

Entera Bio Reports Q3 2023 Financial Results, Highlights Transformational Steps and Unveils Vision as Premier Oral Peptide Company with Five Potential Programs in Development (BioSpace) - "Treatment with Glucagon-Like Peptide-2 (GLP-2) analogs has been shown to improve the absorption of nutrients in patients with short bowel syndrome (SBS) and reduce parenteral support requirements...Entera published pre-clinical data in May 2023 demonstrating that its oral peptide delivery platform enables gastric absorption of teduglutide, as a convenient potential tablet alternative to daily injections. OPKO and Entera expect to update on the program in the first half of 2024....First GLP-1/Glucagon Agonist (Oxyntomodulin) Peptide Tablets for Obesity...Under the collaboration agreement, OPKO will supply certain OXM analogs to combine with Entera’s oral peptide platform. OPKO and Entera expect to update on the program in the first half of 2024."

Clinical • Preclinical • Gastrointestinal Disorder • Metabolic Disorders • Obesity • Short Bowel Syndrome